Psychedelics – News and Features

News
Imaging Biomarker Predicts Response to Rapid Antidepressant
Signals dysfunction in brain system targeted by scopolamine - NIH study.

News
Identifying Protein 'Pockets' that Block Hallucinogens
Psychoactive drugs work by binding proteins in our brains and bodies and although these proteins have been a mystery, new research from the University of North Carolina is illuminating their structures.

News
Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.
Demand in translational science drives need for additional equipment.

News
Drug Boosts Growth Factor to Jump-Start Rapid Antidepressant Response
A study in mice has pinpointed a pivotal new player in triggering the rapid antidepressant response produced by ketamine. By deactivating a little-known enzyme, the drug takes the brakes off rapid synthesis of a key growth factor thought to lift depression.

News
Illicit Drug Use in the Pain Patient Population Decreases with Continued Drug Testing
Researchers from the Millenium Research Institute and the University of Cincinnati have utilised Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for the testing of illicit drugs.

News
CMO Laboratory Expands GMP Manufacturing Capabilities
Pharmatek Laboratories, Inc. have announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities. The company has purchased two roller compactors, a pilot-scale. Both machines have been integrated into Pharmatek’s GMP facility and are ready for GMP manufacturing.

News
Quotient Bioresearch to Highlight Integrated Early Stage Drug Development Platforms at FIP Pharmaceutical Sciences World Congress 2010
The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products with clinical testing.

News
New Hope for Javelin's Pain Candidate but Safety Concerns Remain
An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.

News
Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist
EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.

News
Randox in the Racing World - Sensitive Screening Solutions
Randox are working with the international racing laboratories to maintain the integrity of racing, to make certain animals are winning races on their own natural merits and to ensure the safety of the animals and jockeys is maintained.
Advertisement